Atezolizumab prolongs overall survival over docetaxel in advanced non-small-cell lung cancer patients harboring <i>STK11</i> or <i>KEAP1</i> mutation.

Oncoimmunology · 2021 · PMC7833760 · PMID 33537171

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

15 STK11 or KEAP1 genetic alterations showed highly significant negative associations with the T cell-inflamed gene expression profile in NSCLC. 13 Therefore, it seems that STK11 or KEAP1 mutated (SKmut) patients with NSCLC have inhibitory tumor immune microenvironment and limited benefit from ICIs. 16–18 In addition to immunotherapy, STK11 and KEAP1 mutations

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.